Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Wit Danilkiewicz, David T. Rubin et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 72
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trialMillie Long, James Fon, Jessica R. Allegretti et al.|The Lancet. Gastroenterology & hepatology|2026Cited by 6